Publications
Publications
Show Results For
- All HBS Web
(483)
- Faculty Publications (235)
- September 1995
- Case
Ares-Serono
By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details
Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland; Europe
- April 1995 (Revised April 1999)
- Teaching Note
Aberlyn Capital Management TN
By: Josh Lerner
Teaching Note for (9-294-083). View Details
- October 1994 (Revised November 1994)
- Case
DNA Plant Technology Corporation (DNAP)
By: Ray A. Goldberg and Quintus Travis
Keywords: Biotechnology Industry
- January 1994 (Revised November 1997)
- Case
Aberlyn Capital Management: July 1993
By: Josh Lerner and Peter Tufano
Aberlyn Capital Management, a venture leasing firm specializing in providing capital to biotechnology firms, proposes to introduce a new product. Aberlyn will base a lease on an intangible product: the patent of a biotechnology firm. This poses a series of short and... View Details
- September 1993 (Revised February 1994)
- Case
Calgene, Inc.: Pioneering Agricultural Biotechnology
By: Ray A. Goldberg
- April 1993 (Revised November 1994)
- Case
Chiron Corp.
Pablo Valenzuela, vice president of R&D at Chiron Corp., faces several choices for how to allocate scarce resources across several promising projects. These choices will determine Chiron's position in several emerging biotechnology and diagnostic markets, including... View Details
- April 1993 (Revised October 1995)
- Case
ALZA and Bio-Electro Systems (A): Technological and Financial Innovation
By: Josh Lerner and Peter Tufano
To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,... View Details
- December 1992 (Revised September 1996)
- Case
ImmuLogic Pharmaceutical Corporation (Abridged)
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are... View Details
- October 1992 (Revised November 1997)
- Case
ImmuLogic Pharmaceutical Corporation (A): March 1991
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems... View Details
- May 1992 (Revised February 1996)
- Teaching Note
Nucleon, Inc., Teaching Note
By: Gary P. Pisano
Teaching Note for (9-692-041). View Details
Keywords: Biotechnology Industry
- March 1992 (Revised June 2005)
- Teaching Note
Monsanto's March into Biotechnology (A), Teaching Note
By: Dorothy Leonard-Barton and Alistair D. Williamson
Teaching Note for (9-690-009). View Details
Keywords: Biotechnology Industry
- March 1992
- Case
Amgen, Inc.: Planning the Unplannable
By: Nitin Nohria
By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and... View Details
- February 1992
- Case
U.S. Biotechnology Industry in 1987 (Abridged)
By: Dorothy Leonard-Barton and Alistair D. Williamson
- November 1991
- Case
Monsanto's March into Biotechnology (B)
Monsanto has yet to receive FDA approval for BST, a growth hormone for cows. Anti-BST groups have successfully lobbied Wisconsin and Minnesota, major milk producing states, to ban milk from BST-injected cows; the FDA has charged Monsanto with improperly promoting BST... View Details
- November 1991
- Case
Monsanto's March into Biotechnology (B) (Abridged)
By: Dorothy Leonard-Barton and Alistair D. Williamson
Keywords: Biotechnology Industry
- November 1991 (Revised April 1994)
- Case
Nucleon, Inc.
By: Gary P. Pisano
Nucleon is a small biotechnology company whose first potential product is about to enter clinical testing. Before Nucleon can begin clinical trials, however, its management must decide how and where to manufacture the product. Three options are being contemplated: 1)... View Details
- June 1990 (Revised April 1993)
- Teaching Note
Novo Industri A/S--1981, Teaching Note
By: W. Carl Kester
Teaching Note for (9-286-084). View Details